Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 03, 2022 11:50 ET | Source: Eurobio Scientific

EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF GENDX, INTERNATIONAL HLA DIAGNOSTICS SPECIALIST

EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF GENDX, INTERNATIONAL HLA DIAGNOSTICS SPECIALIST • Acceleration of strategic plan confirming its positioning as a leader in the molecular...
October 03, 2022 11:50 ET | Source: Eurobio Scientific

EUROBIO SCIENTIFIC FINALISE L’ACQUISITION DE GENDX, SPECIALISTE INTERNATIONAL DU DIAGNOSTIC HLA

EUROBIO SCIENTIFIC FINALISE L’ACQUISITION DE GENDX, SPECIALISTE INTERNATIONAL DU DIAGNOSTIC HLA Accélération du plan stratégique confirmant le positionnement d’Eurobio Scientific en tant que leader...
October 03, 2022 09:25 ET | Source: 22nd Century Group, Inc

22nd Century Group (Nasdaq: XXII) Expands VLN® Distributor Network with the Addition of Specialty Distributor Creager Mercantile

Partnership Expands the Availability of VLN® Reduced Nicotine Content Cigarettes to Specialty Point of Sale Retail Sites across Colorado BUFFALO, N.Y., Oct. 03, 2022 (GLOBE NEWSWIRE) -- 22nd...
October 03, 2022 09:00 ET | Source: Timber Pharmaceuticals

Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering

BASKING RIDGE, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company...
October 03, 2022 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate

NEWTON, Mass. and GENEVA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief) today announced...
October 03, 2022 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses

Six presentations and posters between OTS and ESGCT meetings will highlight Wave’s oligonucleotide chemistry advancements as well as RNA editing and RNAi capabilities First presentation in a...
October 03, 2022 08:00 ET | Source: Denali Therapeutics Inc.

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations

Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2LRRK2 mutations are one of the most common genetic drivers of Parkinson’s diseaseTargeting LRRK2 has...
October 03, 2022 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs

Highlights: Phase 1 safety and tolerability study of RECCE® 327 (R327) advancing to a Phase 1b/2a multi-dose and sepsis efficacy studyInitiating two new Phase 2 trials of R327 for the treatment of...
October 03, 2022 08:00 ET | Source: PaxMedica, Inc.

PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors

Founder of several public life sciences companies including Questcor, Osteologix and Indevus, Casamento will serve as an Independent Director TARRYTOWN, NY, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via...
October 03, 2022 08:00 ET | Source: Celularity, Inc.

Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer

FLORHAM PARK, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...